Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

Biotechnology

Healthcare
$27.61 -1.93%

-$0.51 today

Market cap
$3.49B
Beta
1.52
P/E (TTM)
-1400.0
EPS (TTM)
-$0.02
52W Low $13.06High $31.77

Volume 0.84M

Average 1.61M

ARQT Income Before Tax

Profit after all operating and non-operating items but before income tax.

Arcutis Biotherapeutics, Inc.NASDAQ: ARQT

Income Before Tax · Q2 FY2026 · quarter ended Jun 2026

Income before tax turns positive

Q2 FY2026 income before tax was $15.15M, compared with -$15.54M a year earlier. Trailing-twelve-month income before tax was $29.3M.

Context

  • Income before tax amounted to 4.0% of revenue in FY2025, down 66.9 pp from a year earlier.
  • Income before tax grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near $15.15M or moves back toward the trailing-twelve-month quarterly average of $7.32M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$15.15M+235.2% QoQ
Last fiscal yearDec 2025
-$14.97M+89.3% YoY
LTMJun 2026
$29.3M+131.7% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+197.4%——
1 year+89.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(14.97M) USD
Year-over-year change
+89.3%

Income Before Tax vs competitors

How ARQT compares with its peers on the latest reported figures

  • ARQT's LTM Jun 2026 income before tax of $29.3M is the highest of the 6 companies compared; the peer median is -$27.37M.
  • Its year-over-year change of +131.7% is the highest of 4, against a peer median of +52.6%.
  • Income before tax amounts to 6.3% of revenue for ARQT, versus a peer median of 759.9%.
ARQT Competitors Peer median
Income Before Tax for ARQT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARQTArcutis Biotherapeutics, Inc.LTM Jun 2026$29.3M +131.7%—6.3%
SLGLSol-Gel Technologies Ltd.LTM Mar 2026-$1.05M +92.0%—5.7%
TTRXTurn Therapeutics Inc.LTM Mar 2026-$3.84M ———
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$27.37M +52.6%——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$69.66M +46.5%—832.6%
EVMNEvommune, Inc.LTM Mar 2026-$75.99M ——759.9%
Peer median (excluding ARQT) -$27.37M+52.6%—759.9%

Competitors are the stored peer set for ARQT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue03.69M59.61M196.54M376.07M
Cost of Revenue763K754K4.99M19.13M36.7M
Gross Profit(763K)2.93M54.62M177.41M339.38M
Gross Margin—79.5%91.6%90.3%90.2%
Research & Development145.56M182.44M110.58M76.42M77.05M
Selling, General & Admin60.97M122.12M185.15M229.39M274.55M
Operating Expenses205.77M304.56M295.72M305.81M351.6M
Depreciation & Amortization454K934K750K2.6M4.67M
EBITDA(205.9M)(294.87M)(228.57M)(109.63M)1.78M
EBITDA Margin—-7999.8%-383.5%-55.8%0.5%
Operating Income(206.53M)(301.63M)(241.1M)(128.4M)(12.23M)
Operating Margin—-8183.0%-404.5%-65.3%-3.3%
Interest Income173K0000
Interest Expense015.65M29.71M27.17M12.08M
Other Income / Expenses173K(9.83M)(17.93M)(11M)(2.74M)
Income Before Tax(206.36M)(311.46M)(259.03M)(139.39M)(14.97M)
Pre-Tax Margin—-8449.8%-434.6%-70.9%-4.0%
Income Tax Expense003.11M647K1.17M
Net Income(206.36M)(311.46M)(262.14M)(140.04M)(16.14M)
Net Margin—-8449.8%-439.8%-71.3%-4.3%
EPS (Basic)(4.17)(5.66)(3.78)(1.16)(0.13)
EPS (Diluted)(4.17)(5.66)(3.78)(1.16)(0.13)
Weighted Avg Shares49.41M55.03M69.31M120.96M127.23M
Weighted Avg Shares (Diluted)49.41M55.03M69.31M120.96M127.23M

Arcutis Biotherapeutics, Inc.

NASDAQ:ARQT

Intrinsic Alpha fair value

Locked

Current Price

$27.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.